Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the efficacy of pirtobrutinib for patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Using results from the BRUIN MCL-321 (NCT04662255) and BRUIN (NCT03740529) studies, Prof. Wang highlights the promising response rates seen with both covalent BTK inhibitor-naïve and covalent BTK inhibitor pre-treated patients. Prof. Wang concludes by commenting on the potential of pirtobrutinib to improve the outcomes of patients who relapse after covalent BTK inhibitors. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.